Kyverna Therapeutics (KYTX) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Kyverna expects a Q3 2026 loss of $0.68 per share; its earnings call is scheduled for November 12 at 4:00 p.m. ET.
• In the prior quarter, the company reported a loss of $0.63 per share, beating analysts’ estimate of a $0.68 loss. Analysts project losses of $2.70 per share for the current fiscal year and $2.95 for the next.
• Analysts have a “Moderate Buy” consensus rating and an average price target of $29, though ratings include one Sell. Shares recently traded at $5.22, near their 1-year low of $5.09.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) is expected to be announcing its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter. Interested persons may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.63) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.05. On average, analysts expect Kyverna Therapeutics to post ($2.70) EPS for the current fiscal year and ($2.95) EPS for the next fiscal year.

Kyverna Therapeutics Trading Up 1.2%

Shares of KYTX stock traded up $0.06 during trading hours on Wednesday, reaching $5.22. 78,740 shares of the stock traded hands, compared to its average volume of 908,823. The company has a quick ratio of 9.06, a current ratio of 9.06 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $322.87 million, a PE ratio of -1.81 and a beta of 2.12. Kyverna Therapeutics has a 1-year low of $5.09 and a 1-year high of $13.67. The business has a fifty day moving average price of $6.78 and a 200 day moving average price of $8.05.

Analysts Set New Price Targets

A number of analysts have commented on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kyverna Therapeutics in a research report on Monday, September 21st. William Blair upgraded shares of Kyverna Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 23rd. HC Wainwright reiterated a "buy" rating on shares of Kyverna Therapeutics in a research note on Thursday, October 22nd. Benchmark reiterated a "buy" rating on shares of Kyverna Therapeutics in a research note on Friday, September 25th. Finally, Needham & Company LLC set a $25.00 price objective on shares of Kyverna Therapeutics in a report on Friday, September 25th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $29.00.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical-stage biotechnology company developing engineered T-cell therapies for patients with severe autoimmune diseases. The company's approach is designed to selectively eliminate disease-causing B cells, which play a central role in many autoimmune disorders, with the goal of achieving deep and durable disease remission.

Kyverna's lead investigational product, KYV-101, is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The treatment is being evaluated in clinical studies for conditions including lupus nephritis, systemic sclerosis, multiple sclerosis and other serious autoimmune diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.